Irofulven

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)NCT03643107Allarity TherapeuticsPhase 2Completed2021-10-01Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.